Drugmaker Endocyte Rises 29% After Initial Public Offering

Endocyte Inc., a developer of drugs for ovarian and lung tumors, rose 29 percent in Nasdaq trading after today’s initial public offering.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.